{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:33:23Z","timestamp":1769855603856,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited real-world data are available regarding treatment practices and outcomes of multiple myeloma (MM) in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Taiwan Death Registry and used a Markov model to describe disease progression and outcomes in 4092 patients newly diagnosed with MM from 01-Jan-2007 to 31-Dec-2015. We observed marked differences in the characteristics, length and outcome of the clinical journey between patients who did\/did not receive autologous stem cell transplant, and between patients initiated on novel agents versus other treatment regimens. In transplant recipients, initiation with combined thalidomide\u2009+\u2009bortezomib increased over time (12.2\u201377.5%). Progression-free survival after first-line treatment improved and a lower percentage of patients died. Lenalidomide in second and third-line regimens increased (15.5\u201331.5%). In non-transplanted patients, initiation with novel agents increased (17.5\u201354.6%), but death rates remained high (60.3%). The treatment landscape of MM in Taiwan has evolved, with increased use of combined bortezomib\u2009+\u2009thalidomide for first-line and lenalidomide for second\/third-line but many patients die before receiving second-line treatment. Novel agents with different modes of action should be used as early as possible to maximize their benefits. Improved MM treatments remains a critical medical need.<\/jats:p>","DOI":"10.1038\/s41598-020-80607-4","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:15:21Z","timestamp":1610536521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan"],"prefix":"10.1038","volume":"11","author":[{"given":"Yanfang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hsiun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Siggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"80607_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca, R. et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia 31, 1915\u20131921 (2017).","journal-title":"Leukemia"},{"key":"80607_CR2","first-page":"6848902","volume":"2016","author":"X Wang","year":"2016","unstructured":"Wang, X., Li, Y. & Yan, X. Efficacy and safety of novel agent-based therapies for multiple myeloma: A meta-analysis. Biomed. Res. Int. 2016, 6848902 (2016).","journal-title":"Biomed. Res. Int."},{"key":"80607_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"80607_CR4","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"80607_CR5","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1016\/S1470-2045(13)70404-2","volume":"14","author":"D Tan","year":"2013","unstructured":"Tan, D. et al. Management of multiple myeloma in Asia: Resource-stratified guidelines. Lancet Oncol. 14, e571\u2013e581 (2013).","journal-title":"Lancet Oncol."},{"key":"80607_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"80607_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","volume":"66","author":"CH Tang","year":"2020","unstructured":"Tang, C. H., Hou, H. A., Huang, K. C., Qiu, H. & Liu, Y. Treatment evolution and improved survival in multiple myeloma in Taiwan. Ann. Hematol. 66, 321\u2013330 (2020).","journal-title":"Ann. Hematol."},{"key":"80607_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song, X., Cong, Z. & Wilson, K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr. Med. Res. Opin. 32, 95\u2013103 (2016).","journal-title":"Curr. Med. Res. Opin."},{"key":"80607_CR9","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1080\/10428194.2018.1448084","volume":"59","author":"L Gengenbach","year":"2018","unstructured":"Gengenbach, L. et al. Navigating the changing multiple myeloma treatment landscape: Clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leuk Lymphoma 59, 2692\u20132699 (2018).","journal-title":"Leuk Lymphoma"},{"key":"80607_CR10","doi-asserted-by":"publisher","first-page":"e13026","DOI":"10.1111\/ecc.13026","volume":"28","author":"L Antunes","year":"2019","unstructured":"Antunes, L. et al. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. Eur. J. Cancer Care (Engl) 28, e13026 (2019).","journal-title":"Eur. J. Cancer Care (Engl)"},{"key":"80607_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.16124","volume":"188","author":"VT de Moraes Hungria","year":"2020","unstructured":"de Moraes Hungria, V. T. et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016. Br. J. Haematol. 188, 383\u2013393 (2020).","journal-title":"Br. J. Haematol."},{"key":"80607_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","volume":"9","author":"S Jagannath","year":"2016","unstructured":"Jagannath, S. et al. Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices. Expert Rev. Hematol. 9, 707\u2013717 (2016).","journal-title":"Expert Rev. Hematol."},{"key":"80607_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig, H. et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J. Clin. Oncol. 28, 1599\u20131605 (2010).","journal-title":"J. Clin. Oncol."},{"key":"80607_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2147\/CIA.S142507","volume":"12","author":"ZY Liu","year":"2017","unstructured":"Liu, Z. Y. et al. Association between serum beta2-microglobulin levels and frailty in an elderly Chinese population: Results from RuLAS. Clin. Interv. Aging 12, 1725\u20131729 (2017).","journal-title":"Clin. Interv. Aging"},{"key":"80607_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa, L. J. et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 1, 282\u2013287 (2017).","journal-title":"Blood Adv."},{"key":"80607_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab, M. S. et al. Multiple myeloma: Practice patterns across Europe. Br. J. Haematol. 175, 66\u201376 (2016).","journal-title":"Br. J. Haematol."},{"key":"80607_CR17","doi-asserted-by":"publisher","first-page":"e0208507","DOI":"10.1371\/journal.pone.0208507","volume":"13","author":"K Remes","year":"2018","unstructured":"Remes, K. et al. Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009\u20132013. PLoS ONE 13, e0208507 (2018).","journal-title":"PLoS ONE"},{"key":"80607_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Clinical profiles of multiple myeloma in Asia\u2014An Asian Myeloma Network study. Am. J. Hematol. 89, 751\u2013756 (2014).","journal-title":"Am. J. Hematol."},{"key":"80607_CR19","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/cncr.30747","volume":"123","author":"JR Schriber","year":"2017","unstructured":"Schriber, J. R. et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer 123, 3141\u20133149 (2017).","journal-title":"Cancer"},{"key":"80607_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00277-016-2882-9","volume":"96","author":"YC Cohen","year":"2017","unstructured":"Cohen, Y. C. et al. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: A retrospective national multi-site cohort study. Ann. Hematol. 96, 271\u2013278 (2017).","journal-title":"Ann. Hematol."},{"key":"80607_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed, R., Bazarbachi, A. H., Malard, F., Harousseau, J. L. & Mohty, M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 9, 44 (2019).","journal-title":"Blood Cancer J."},{"key":"80607_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000357394","volume":"132","author":"S Ozaki","year":"2014","unstructured":"Ozaki, S. et al. Survival of multiple myeloma patients aged 65\u201370 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 132, 211\u2013219 (2014).","journal-title":"Acta Haematol."},{"key":"80607_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/17571472.2010.11493315","volume":"3","author":"TY Wu","year":"2010","unstructured":"Wu, T. Y., Majeed, A. & Kuo, K. N. An overview of the healthcare system in Taiwan. Lond. J. Prim. Care (Abingdon) 3, 115\u2013119 (2010).","journal-title":"Lond. J. Prim. Care (Abingdon)"},{"key":"80607_CR24","unstructured":"National Health Insurance Research Database. Taiwan. http:\/\/nhird.nhri.org.tw\/en\/index.htm (2013)."},{"key":"80607_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jpsychires.2012.12.007","volume":"47","author":"FH Chou","year":"2013","unstructured":"Chou, F. H., Tsai, K. Y. & Chou, Y. M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: A nine-year follow-up study. J. Psychiatr. Res. 47, 460\u2013466 (2013).","journal-title":"J. Psychiatr. Res."},{"key":"80607_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.schres.2014.09.032","volume":"159","author":"KY Tsai","year":"2014","unstructured":"Tsai, K. Y. et al. The risks of major osteoporotic fractures in patients with schizophrenia: A population-based 10-year follow-up study. Schizophr. Res. 159, 322\u2013328 (2014).","journal-title":"Schizophr. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80607-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:57:28Z","timestamp":1670032648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80607-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80607"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80607-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, HQ and YL are employees of Janssen Research & Development LLC and hold stock in Johnson & Johnson. CHT and HAH declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1112"}}